Choose a folder
DISCOVER Study and CaReMe Registry: shaping diabetes treatment worldwide
Diabetes is a large and growing global public health crisis, with a total of 463 million sufferers worldwide in 2019 – a figure that is estimated to rise to 700 million by 2045, with type 2 diabetes (T2D) accounting for the vast majority of cases.1
The DISCOVER study
The pioneering DISCOVER study was launched in 2015 to fill the knowledge gap resulting from a lack of data on treatment patterns and associated outcomes in people with T2D from low- and middle-income countries. This was to be achieved by observing patient characteristics and diabetes treatment patterns in patients with T2D initiating second-line glucose-lowering therapy. The global, prospective, non-interventional study aimed to chart the evolution of disease management and clinical outcomes in real world settings over a 3-year period. This involved using data collection during routine visits from three different sources:
Data were collected at five time points (at the start of the study, and then at 6, 12, 24, and 36 months, with 36 months being the last data collection time point), anonymized, and sent to a central database for analysis.
The CaReMe Registry
In preparation for the completion of the DISCOVER study in August 2019, the DISCOVER Global Registry was launched to build on the success of DISCOVER and enable continued data collection on a global scale. Following the year-long pilot phase of the DISCOVER Global Registry which ended on December 31, 2018, full rollout of the DISCOVER Global Registry commenced in January 2019.
Diabetes is often associated with cardiovascular and renal comorbidities.2 To reflect this, the scope of the DISCOVER Global Registry was expanded from initial data collection on patients with T2D. The registry developed into the CaReMe Registry, which aims to gain holistic insights into cardiac, renal and metabolic conditions in order to provide a clear picture of these three tightly linked pathologies.
The CaReMe Registry expands the parameters for data acquisition, utilizing a cloud-based eCRF to provide the maximum possible capacity for further data collection.
The real world data that the CaReMe Registry continues to collect will provide insights into patient characteristics, risk factors for disease progression, treatment patterns, and development of complications. This information can then be used to improve patient care and quality of life by assessing clinical outcomes and will allow participating physicians to benchmark their performance against clinical guidelines.
The CaReMe Registry revolutionizes patient care in cardiac, renal and metabolic conditions
CaReMe Registry enrollment status*
All eligible patients, who are aged 18 years or over and have provided written consent, will continue to be enrolled into the registry, and their data (e.g. healthcare provider, treatment patterns, factors influencing therapy alterations, disease control, quality of care indicators, and outcomes) will be uploaded incrementally after additional follow-up and routine clinic visits.
Following the success of the pilot phase, and with the participation of additional countries and healthcare professionals, in-depth data analysis is now being undertaken by leading academic centers (National Heart Centre Singapore and Saint Luke's Mid America Heart Institute) with results being made accessible to the DISCOVER Global Registry Scientific Committee and to National Coordinators.
The CaReMe Registry is the first global registry of cardio-renal-metabolic disease with the capability to serve the unmet needs of emerging markets
By seeking to provide long-term follow-up data beyond the completion of the DISCOVER study, the CaReMe Registry will enable the collection of quality key performance indicators for benchmarking and improving quality of care, as well as the collection of data on real world management of diabetes and associated complications taken from a wide geographical sample. The CaReMe Registry is the first global registry of cardio-renal-metabolic disease with the capability to serve the unmet needs of emerging markets in which 320 million people live with diabetes and the availability of comprehensive data is limited.
In this way, real world registry data can be used to inform public health resource allocation directly, to conduct pre-trial feasibility analyses, and to serve as a platform for post-approval surveillance of new drugs.